| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T452 |
0-187 |
Sentence |
denotes |
Importantly, low micromolar concentrations of cyclosporin A (<35 µM) substantially impacted the replication of SARS-CoV, human coronavirus 229E, and mouse hepatitis virus in cell culture. |
| T453 |
188-269 |
Sentence |
denotes |
Cyclosporin A significantly inhibited gene expression and reduced progeny titers. |
| T454 |
270-354 |
Sentence |
denotes |
Cyclosporin A treatment completely blocked SARS-CoV RNA and protein synthesis [196]. |
| T455 |
355-526 |
Sentence |
denotes |
Cyclosporine A also in vitro reduced the replication of MERS-CoV, transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and feline coronavirus [196]. |
| T456 |
527-601 |
Sentence |
denotes |
In fact, cyclosporine A has demonstrated broad-spectrum antiviral effects. |
| T457 |
602-658 |
Sentence |
denotes |
It inhibited the replication of HBV, HCV, and HIV [197]. |
| T458 |
659-904 |
Sentence |
denotes |
Cyclosporine also inhibited the replication of Zika virus, West Nile virus, Rift Valley fever virus, and influenza A virus by blocking the interaction of cellular cyclophilins with viral proteins as well as by inhibiting the RNA synthesis [198]. |
| T459 |
905-982 |
Sentence |
denotes |
By targeting cyclophilins, the drug can also prevent acute lung injury [199]. |
| T460 |
983-1264 |
Sentence |
denotes |
Currently, the use of cyclosporin A is being tested in patients with moderate COVID-19 (NCT04412785; n = 20), hospitalized COVID-19 patients (NCT04392531; n = 120), and combined with topical corticosteroid in COVID-19 patients with acute keratoconjunctivitis (NCT04451239; n = 12). |
| T461 |
1265-1324 |
Sentence |
denotes |
It has also been used in psoriatic COVID-19 patients [200]. |
